{
    "url_original": "https://www.wsj.com/articles/lilly-alzheimers-drug-helped-patients-in-small-trial-11610364603?mod=business_lead_pos3",
    "url": "lilly-alzheimers-drug-helped-patients-in-small-trial-11610364603",
    "title": "Lilly Alzheimer’s Drug Helped Patients in Small Trial",
    "sub_head": "Donanemab slowed cognitive and functional decline of patients with mild Alzheimer’s by 32% compared with placebo",
    "category_1": "Business",
    "category_2": "Health Care",
    "image_1_url": "https://images.wsj.net/im-283311?width=620&size=1.5",
    "image_1": "im-283311.jpg",
    "time": "2021-01-11 06:30:00",
    "body": "An experimental Alzheimer’s drug from  Eli Lilly  & Co. helped patients in a small trial, the company said Monday, renewing hopes that researchers are closing in on therapies that can fight the disease.<br />The drug slowed the decline in memory and ability to perform activities of daily living by 32% after 18 months among people who received the therapy compared with those who got a placebo, Lilly said.<br />Lilly’s drug, named donanemab, met the primary goal of the study, according to the company—a milestone one experimental Alzheimer’s drug after another has failed to reach.<br />“It’s a big moment for Alzheimer’s patients. There’s hope again,” said Daniel Skovronsky, Lilly’s chief scientific officer.<br />Lilly gave only the highlights of the study results, saying details would follow at a medical meeting and in an article in a peer-reviewed journal."
}